Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13343762 | 1.00 | LTA4H (0.54) | LTA4HLMNAALDH1A1GRM2MCHR1 | |
| SCHEMBL3158273 | 0.90 | LMNA (0.57) | LTA4HLMNAALDH1A1SIGMAR1HRH3 | |
| SCHEMBL18082551 | 0.86 | LTA4H (0.55) | LTA4HLMNAALDH1A1SIGMAR1 | |
| SCHEMBL21092817 | 0.85 | LTA4H (0.52) | LTA4HALDH1A1HRH3 | |
| SCHEMBL1241949 | 0.84 | LTA4H (0.54) | LTA4HALDH1A1SIGMAR1HRH3OPRM1 | |
| SCHEMBL1240977 | 0.84 | LTA4H (0.54) | LTA4HALDH1A1SIGMAR1HRH3OPRM1 | |
| SCHEMBL1240978 | 0.84 | LTA4H (0.54) | LTA4HALDH1A1SIGMAR1HRH3OPRM1 | |
| SCHEMBL3271398 | 0.84 | LTA4H (0.60) | LTA4HALDH1A1MCHR1SIGMAR1 | |
| SCHEMBL4512639 | 0.84 | LTA4H (0.60) | LTA4HALDH1A1MCHR1SIGMAR1 | |
| SCHEMBL15156984 | 0.84 | LTA4H (0.48) | LTA4HGRM2MCHR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | LTA4H 2746/4885LMNA 3429/4885ALDH1A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.